Amelioration of delayed-type hypersensitivity responses by IL-27 administration

Area of Science:

• Immunology
• Cytokine Biology
• Inflammation Research

Background:

• Interleukin 27 (IL-27) is part of the IL-12 cytokine family.
• Previous studies suggested immunosuppressive functions of IL-27, but its in vivo role and therapeutic potential were unclear.
• WSX-1 (IL-27 receptor alpha chain) deficient mice and in vitro data hinted at IL-27's immunosuppressive capacity.

Purpose of the Study:

• To investigate the in vivo effect of Interleukin 27 (IL-27) administration on delayed-type hypersensitivity (DTH).
• To elucidate the therapeutic potential of IL-27 in immune-mediated conditions.

Main Methods:

• Utilized WSX-1 deficient mice to assess DTH responses.
• Administered recombinant IL-27 to experimental models.
• Measured footpad swelling as an indicator of DTH.
• Analyzed the activation status of draining lymph node cells.

Main Results:

• WSX-1 deficient mice exhibited heightened DTH responses, indicated by increased footpad swelling.
• Administration of IL-27 significantly reduced footpad swelling in the DTH model.
• IL-27 deficiency did not alter the activation status of lymph node cells, suggesting an effect on the effector phase.

Conclusions:

• Interleukin 27 (IL-27) demonstrates a suppressive effect on activated T cells in vivo.
• IL-27 ameliorates delayed-type hypersensitivity responses.
• IL-27 holds therapeutic potential for diseases driven by immune dysregulation.